Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioTrove, Inc. Announces Collaborative Agreement with Pfizer, Inc.


Business Editors and Health/Medical Writers

BIOWIRE2K

CAMBRIDGE, Mass.--(BW HealthWire)--Jan. 12, 2001

BioTrove, Inc., formerly Advanced Instrumentation instrumentation, in music: see orchestra and orchestration.
instrumentation

In technology, the development and use of precise measuring, analysis, and control equipment.
 Systems, Inc., announced today it has entered into a collaborative research agreement with Pfizer Inc. (NYSE NYSE

See: New York Stock Exchange
:PFE 1. (text, editor) PFE - Programmer's File Editor.
2. (language) PFE - Portable Forth Environment.
) for the development of BioTrove's ultra-high throughput screening technology for use in Pfizer's research facilities.

Under the terms of the two-year agreement, BioTrove will develop a ultra-high throughput screening platform integrating proprietary nanoscale At nanometer size. Any device only a few nanometers in size is nanoscale. See nanotechnology and nanometer.  liquid handling technologies to be purchased by Pfizer for use by Pfizer research sites. "BioTrove is extremely pleased to have entered into this relationship with Pfizer." said Colin Brenan, Ph.D., Chief Executive Officer and co-founder of BioTrove, Inc. "Pfizer is an innovative research-based company that has recognized the value of technological innovation in accelerating the drug discovery process. BioTrove has created advanced technology purposely pur·pose·ly  
adv.
With specific purpose.


purposely
Adverb

on purpose
USAGE: See at purposeful.

Adv. 1.
 designed to speed the analysis of drug compounds in nanoliter volume assays and at high rates. We believe that BioTrove's system will be of great benefit to Pfizer and other companies to accelerate drug development and design"

BioTrove is a privately-held company providing innovative technological solutions to the life science industry. Their proprietary drug discovery technology platforms are designed to substantially increase the efficiency of the entire pre-clinical drug discovery process from combinatorial chemistry Combinatorial chemistry involves the rapid synthesis or the computer simulation of a large number of different but structurally related molecules. Introduction
Synthesis of molecules in a combinatorial fashion can quickly lead to large numbers of molecules.
, target identification, through high-performance screening and profiling, to ADME/Tox studies.

Source: BioTrove, Inc.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 12, 2001
Words:222
Previous Article:Record Deliveries in Western Europe for Volvo Trucks in 2000.
Next Article:Amber Diagnostics Continues to Grow With Remanufactured Pain Management C-arms.
Topics:



Related Articles
Spotfire Licenses Decision Analytics Software to Pfizer Drug Discovery Researchers Worldwide.
Virbac Licenses Two Equine Products to Pfizer Inc; Company Expects to Achieve Annual Pretax Income of $4.7 Million.
Pfizer Licenses Battelle Pulmonary Therapeutics Delivery Technology, Makes Equity Investment in Battelle Spinoff.
Inceutica Announces Drug Research and Development Outsourcing Agreement With Pfizer Inc; Pharmaceutical Giant to Conduct Contract Drug Development...
Oncolytics Biotech Inc. Enters Agreement With Pfizer Inc.
Gene Logic Expands Agreement with Pfizer to Co-Develop Custom Toxicology Microarray.
Strategic INFO Enters into Licensing Agreement with Pfizer Inc.
Argonaut Announces Collaboration with Pfizer Inc.
Albany Molecular Research, Inc. Announces Agreement with Pfizer Inc.
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles